Sintilimab, created by Innovbio , represents a crucial advance in cancer management. This protein medicine is a PD-1 antagonist, meant to unlock the patient's system against malignant growths . Medical https://www.targetmol.com/compound/sintilimab_%28anti-pd-1%29